diff --git a/pages/STOP2030___Viaje a Ghana 2023.md b/pages/STOP2030___Viaje a Ghana 2023.md index acc6d1f5..220dd5f4 100644 --- a/pages/STOP2030___Viaje a Ghana 2023.md +++ b/pages/STOP2030___Viaje a Ghana 2023.md @@ -23,15 +23,15 @@ date:: [[2023/12]] - Week 22-26 Jan, 2024, to incorporate comments by [[ISGlobal]] - [[ISGlobal]] convene virtual discussion on protocol to address emerging/outstanding comments - IRB Submissions - - ISGlobal responsible for submission of documents + - [[ISGlobal]] responsible for submission of documents - Ghana submit by 1 Feb in advance of 7 Feb 2024 deadline (5 March as backup) - [[GHS/RDD]] will notify of supporting documents needed for the IRB - Training - R&D/ISGlobal - Good Clinical Practice (can be GFDA or from different organization as long as not expired) - Reference lab - - Samples should be run on site (Kato Katz in the schools) and others in-country (ELISA dried blood spots for Strongyloides), with a lab in Accra still to be identified. - - Communication & Social mobilization - NTD Programme/RDD/Health Promotion/Mundo Sano - - Frame messaging on why doing clinical trial as based on Trichuris burden – evidence for clinical trial most clear as albendazole is less effective and we have decent burden data; Reinforce messaging that will be a clinical trial, building on and using MDA architecture as much as possible + - Samples should be run on site (Kato Katz in the schools) and others in-country (ELISA dried blood spots for [[Strongyloides]]), with a lab in Accra still to be identified. + - Communication & Social mobilization - NTD Programme/ [[GHS/RDD]]/Health Promotion/Mundo Sano + - Frame messaging on why doing clinical trial as based on [Trichuris] burden – evidence for clinical trial most clear as albendazole is less effective and we have decent burden data; Reinforce messaging that will be a clinical trial, building on and using MDA architecture as much as possible - GHS to review external communications plan – Tuesday 19th - All/Mundo Sano facilitate - Circulate and review materials from past MDA and/or relevant trials from communications/social mobilization (GHS has already circulated)